Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China.
Ir J Med Sci. 2019 Aug;188(3):761-764. doi: 10.1007/s11845-018-1912-0. Epub 2018 Oct 17.
Adjuvant chemotherapeutics and prophylactic cranial irradiation (PCI) are both recommended in the National Comprehensive Cancer Network (NCCN) guidelines for treating individuals suffering from surgically resected pT1-2N0M0 small cell lung cancer (SCLC). Whether adjuvant chemotherapy combined with PCI is superior to adjuvant chemotherapy alone in these patients is largely unknown. PCI may therefore be with uncertain effects in surgically resected pT1-2N0M0 SCLC.
辅助化疗和预防性颅脑照射（PCI）均被推荐用于治疗手术切除的 pT1-2N0M0 小细胞肺癌（SCLC）患者的国家综合癌症网络（NCCN）指南中。辅助化疗联合 PCI 是否优于单纯辅助化疗，目前在这些患者中还知之甚少。因此，PCI 可能对手术切除的 pT1-2N0M0 SCLC 疗效不确定。
